Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Payables (2020 - 2025)

Biofrontera has reported Payables over the past 6 years, most recently at $4.9 million for Q4 2025.

  • For Q4 2025, Payables rose 14.6% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $4.9 million, up 14.6%, while the annual FY2025 figure was $4.9 million, 14.6% up from the prior year.
  • Payables for Q4 2025 was $4.9 million at Biofrontera, down from $6.6 million in the prior quarter.
  • Over five years, Payables peaked at $11.0 million in Q3 2023 and troughed at $269000.0 in Q1 2022.
  • A 5-year average of $5.1 million and a median of $4.7 million in 2024 define the central range for Payables.
  • Biggest five-year swings in Payables: surged 1551.06% in 2022 and later tumbled 57.83% in 2024.
  • Year by year, Payables stood at $658000.0 in 2021, then surged by 1551.06% to $10.9 million in 2022, then dropped by 22.76% to $8.4 million in 2023, then plummeted by 49.08% to $4.3 million in 2024, then increased by 14.6% to $4.9 million in 2025.
  • Business Quant data shows Payables for BFRI at $4.9 million in Q4 2025, $6.6 million in Q3 2025, and $5.8 million in Q2 2025.